GlassScriptPhysician profile
Curtiss Walter Combs
NPI 1710925409
$2,593.81
in general payments reported to CMS, 2019-2025
24 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $252 · 2021: $593 · 2022: $458 · 2023: $119 · 2024: $167 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $656.37 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $471.39 | 2021-2024 | Ubrelvy, Qulipta |
| Amgen INC. | $212.93 | 2019-2025 | Otezla, Repatha, Tepezza |
| Pfizer INC. | $116.23 | 2019-2021 | |
| Amarin Pharma, INC. | $112.60 | 2019-2021 | |
| Dexcom, INC. | $105.27 | 2021-2025 | Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.27 | 2019 | |
| Corcept Therapeutics | $83.97 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $83.21 | 2021-2025 | Eliquis |
| Allergan, INC. | $77.41 | 2019-2020 | |
| Hologic Sales and Service, LLC | $74.13 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Lilly USA, LLC | $65.28 | 2020-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $60.55 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $58.03 | 2025 | Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $54.88 | 2019-2024 | Arexvy, Trelegy Ellipta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.89 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $46.36 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $44.06 | 2019-2025 | Breztri |
| Sanofi-Aventis U.S. LLC | $35.71 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.39 | 2022 | |
| Merck Sharp & Dohme LLC | $17.66 | 2022 | |
| Spinal Simplicity, LLC | $15.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.15 | 2022 | |
| Abiomed | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtiss Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.